Publication Information

{'id': 'https://openalex.org/W2254126652', 'doi': None, 'title': 'Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer', 'display_name': 'Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer', 'publication_year': 2009, 'publication_date': '2009-02-01', 'ids': {'openalex': 'https://openalex.org/W2254126652', 'mag': '2254126652'}, 'language': 'ko', 'primary_location': {'is_oa': False, 'landing_page_url': 'http://dspace.kci.go.kr/handle/kci/917775', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S162267923', 'display_name': 'The Korean Journal of Internal Medicine', 'issn_l': '1226-3303', 'issn': ['1226-3303', '2005-6648'], 'is_oa': True, 'is_in_doaj': True, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320408', 'host_organization_name': 'Korean Association of Internal Medicine', 'host_organization_lineage': ['https://openalex.org/P4310320408'], 'host_organization_lineage_names': ['Korean Association of Internal Medicine'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': [], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5083147750', 'display_name': '문대성', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': '문대성 ( Dae Sung Moon )', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5088709796', 'display_name': '장태원', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': '장태원 ( Tae Won Jang )', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5072446620', 'display_name': '옥철호', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': '옥철호 ( Chul Ho Oak )', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5076560749', 'display_name': '정만홍', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': '정만홍 ( Maan Hong Jung )', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5058610437', 'display_name': '김도현', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': '김도현 ( Do Hyun Kim )', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5028684657', 'display_name': '최인수', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': '최인수 ( In Soo Choi )', 'raw_affiliation_strings': [], 'affiliations': []}], 'institution_assertions': [], 'countries_distinct_count': 0, 'institutions_distinct_count': 0, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': {'value': 500, 'currency': 'USD', 'value_usd': 500, 'provenance': 'doaj'}, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 64}, 'biblio': {'volume': '76', 'issue': '2', 'first_page': '179', 'last_page': '185'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10417', 'display_name': 'Lung Cancer Treatments and Mutations', 'score': 0.9998, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10417', 'display_name': 'Lung Cancer Treatments and Mutations', 'score': 0.9998, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10696', 'display_name': 'Gastric Cancer Management and Outcomes', 'score': 0.9953, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11067', 'display_name': 'Colorectal Cancer Treatments and Studies', 'score': 0.9848, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/erlotinib-hydrochloride', 'display_name': 'Erlotinib Hydrochloride', 'score': 0.6196291}], 'concepts': [{'id': 'https://openalex.org/C2778087573', 'wikidata': 'https://www.wikidata.org/wiki/Q418369', 'display_name': 'Erlotinib', 'level': 4, 'score': 0.9934933}, {'id': 'https://openalex.org/C2780580887', 'wikidata': 'https://www.wikidata.org/wiki/Q417824', 'display_name': 'Gefitinib', 'level': 4, 'score': 0.9878844}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.86469644}, {'id': 'https://openalex.org/C2776256026', 'wikidata': 'https://www.wikidata.org/wiki/Q47912', 'display_name': 'Lung cancer', 'level': 2, 'score': 0.6342374}, {'id': 'https://openalex.org/C2909325608', 'wikidata': 'https://www.wikidata.org/wiki/Q418369', 'display_name': 'Erlotinib Hydrochloride', 'level': 5, 'score': 0.6196291}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.45441613}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.4501231}, {'id': 'https://openalex.org/C2779438470', 'wikidata': 'https://www.wikidata.org/wiki/Q424401', 'display_name': 'Epidermal growth factor receptor', 'level': 3, 'score': 0.43135282}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.32766914}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.25811577}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'http://dspace.kci.go.kr/handle/kci/917775', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S162267923', 'display_name': 'The Korean Journal of Internal Medicine', 'issn_l': '1226-3303', 'issn': ['1226-3303', '2005-6648'], 'is_oa': True, 'is_in_doaj': True, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320408', 'host_organization_name': 'Korean Association of Internal Medicine', 'host_organization_lineage': ['https://openalex.org/P4310320408'], 'host_organization_lineage_names': ['Korean Association of Internal Medicine'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'id': 'https://metadata.un.org/sdg/3', 'score': 0.75, 'display_name': 'Good health and well-being'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 24, 'referenced_works': ['https://openalex.org/W1839238860', 'https://openalex.org/W1969658446', 'https://openalex.org/W1970476748', 'https://openalex.org/W1979332174', 'https://openalex.org/W1987709860', 'https://openalex.org/W2011701047', 'https://openalex.org/W2021966502', 'https://openalex.org/W2031056915', 'https://openalex.org/W2049484790', 'https://openalex.org/W2118128235', 'https://openalex.org/W2130652363', 'https://openalex.org/W2135836172', 'https://openalex.org/W2138297714', 'https://openalex.org/W2139236349', 'https://openalex.org/W2139377071', 'https://openalex.org/W2140775102', 'https://openalex.org/W2142862394', 'https://openalex.org/W2146404049', 'https://openalex.org/W2153477391', 'https://openalex.org/W2159023488', 'https://openalex.org/W2167368130', 'https://openalex.org/W2285582134', 'https://openalex.org/W2504684570', 'https://openalex.org/W3159004246'], 'related_works': [], 'abstract_inverted_index': {'목적:': [0], '우리나라에서': [1], '비소세포폐암의': [2], '발생': [3], '빈도는': [4], '증가하는': [5], '추세에': [6], '있다.': [7, 29], '여성': [8, 63], '폐암은': [9], '대부분이': [10], '비흡연자이고': [11], '선암이': [12], '주로': [13], '발병하는': [14], '것으로': [15], '알려지고': [16], '있으며': [17], '표피성장인자수용체의': [18], '티록신': [19], '키나아제': [20], '억제제가': [21], '동양인': [22], '여성에서': [23], '더': [24, 205], '효과가': [25], '있다는': [26], '것이': [27], '알려져': [28], '본': [30], '연구는': [31], 'gefitinib과': [32], 'eroltinib은': [33], '작용기전은': [34], '비슷하나': [35], '용량의': [36], '차이가': [37], '있어': [38], '각각의': [39], '치료': [40, 48, 75, 132, 148, 193], '성적이': [41], '보고자': [42, 51], '마다': [43], '조금씩': [44], '달라': [45], '두': [46], '약제의': [47], '성적을': [49], '비교하여': [50], '하였다.': [52], '방법:': [53], '2004년': [54], '2월': [55], '2007년': [56], '4월까지': [57], '고신대학교': [58], '복음병원에서': [59], '진단': [60], '및': [61, 196], '치료받은': [62], '폐암': [64], '환자들을': [65], '의무기록을': [66], '통해': [67], '후향적으로': [68], '조사했다.': [69], '한달': [70], '이상': [71], 'gefitinib,': [72], 'erlotinib을': [73, 124], '복용하고': [74], '평가가': [76], '가능한': [77], '환자를': [78], '대상으로': [79], '생존기간,': [80], '약물투여': [81], '기간,': [82], '독성의': [83], '발생빈도를': [84], '비교': [85], '분석하였다.': [86], '결과:': [87], '전체': [88], '환자는': [89], '42명이었고,': [90], 'gefitinib': [91], '치료군은': [92, 95], '26명,': [93], 'erlotinib': [94], '16명이었다.': [96], '나이의': [97], '중간값은': [98], '58세였고,': [99], '85%가': [100], '비흡연가,': [101], '83%가': [102], '선암이었으며,': [103], '병기는': [104], 'IIIb가': [105], '13명(24.0%),': [106], 'IV가': [107], '16명(76%)이고,': [108], '생존일': [109], '중앙값은': [110, 170], '793일이었다.': [111], 'gefitinib으로': [112], '치료한': [113], '군이': [114], '26명(62%)이었고,': [115], '이': [116, 121], '중': [117, 127], '18명(69.2%)이': [118], '3차': [119], '화학요법으로': [120], '약제를': [122], '사용하였고,': [123], '사용한': [125], '16명': [126], '12명(87.5%)이': [128], '2차약으로': [129], '사용하였다.': [130], '전체적인': [131], '반응율은': [133, 149], '14명에서': [134], '부분': [135], '관해를': [136], '보여': [137], '33.3%의': [138], '반응율을': [139], '보였고,': [140], '안정성': [141], '병변을': [142], '포함한': [143], '질병': [144], '조절율은': [145], '76.2%이었다.': [146], 'gefitinib군의': [147], '39%,': [150], 'erlotinib군': [151, 185], '31%이었으며': [152], '양군': [153], '간의': [154], '통계적': [155, 164, 178], '차이는': [156, 165, 199], '없었고,': [157], '평균': [158], '생존': [159], '기간이': [160], '각각': [161], '651일,': [162], '510일이었으나': [163], '없었다.': [166, 180, 200], '약제': [167, 197], '투여': [168], '기간의': [169], 'gefitinib군에서': [171], '186일,': [172], 'erlotinib군이': [173], '262일로': [174], 'erlotinib군에서': [175, 187], '길었으나': [176], '역시': [177], '유의성은': [179], '피부': [181, 202], '독성은': [182], 'gefitinib군이': [183], '27%,': [184], '75%로': [186], '많이': [188], '나타났다.': [189, 207], '결론:': [190], 'Gefitinib군과': [191], 'erlotinib군의': [192], '반응율과': [194], '생존기간': [195], '투여기간의': [198], 'Erlotinib군에서': [201], '발진': [203], '빈도가': [204], '높게': [206]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2254126652', 'counts_by_year': [], 'updated_date': '2024-12-12T06:58:22.613485', 'created_date': '2016-06-24'}